NPM1 and acute myeloid leukemia: Moreover, a retrospective study of elderly NPM1-mutated AML patients with positive NPM1-measurable residual disease (MRD), indicated that initiation of venetoclax, following induction and consolidation of chemotherapy together with azacytidine or LDAC, induces rapid clearance of residual NPM1-blasts (161).